In focus · trending topic

treatment of

1 stories · following the connections

Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of peripheral T-cell lymphoma (PTCL)

By Nasdaq OMXDec 22, 2017, 1:00 PM UTC